Contents

Razi Cov Pars

Razi Cov Pars

Vaccine description
Target	SARS-CoV-2
Vaccine type	Protein subunit
Clinical data
Routes of administration	Intramuscular, Intranasal
Legal status
Legal status	Full list of Razi Cov Pars authorizations

Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health symptoms Migration Military Notable deaths Other health issues Politics diplomacy Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Society Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

Razi Cov Pars (Persian: رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute Razi Cov Pars is a covid-19 vaccine based on recombinant protein, which is being produced by Razi Vaccine and Serum Research Institute, Iran. This vaccine is the first injectable-intranasal recombinant protein corona vaccine.^[1][2][3]It's the second Iranian COVID-19 vaccine reaching human trials^[1] and is currently in phase IIIofclinical research during which it's compared to the Sinopharm BIBP vaccine.^[4][5]

Medical uses[edit]

It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray).^[3]

Pharmacology[edit]

Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein.^[2]

Manufacturing[edit]

It's planned to produce one million doses of the vaccine each month as of September 2021.^[4]

As of 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health.^[6]

History[edit]

Clinical trials[edit]

See also[edit]

• Pharmaceuticals in Iran
• COVID-19 pandemic in Iran
• COVID-19 vaccine clinical research

References[edit]

Further reading[edit]

Scholia has a profile for Razi Cov Pars (Q106725976).

Viruses

COVID-19

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

This article about vaccinesorvaccination is a stub. You can help Wikipedia by expanding it.